期刊文献+

治疗高脂血症的新药研究进展 被引量:34

Advances in studies on new drugs used for treatment of hyperlipidemia
原文传递
导出
摘要 高脂血症是动脉粥样硬化的危险因素,与冠心病、中风及股动脉狭窄等病症息息相关,严重威胁人类健康。他汀类药物因确切的疗效,已成为大多数临床医生的首选。但大剂量服用他汀类药物会产生肌毒和肝转氨酶升高,并不适用于所有的心血管类疾病。此外贝特类和烟酸类药物会产生胃肠道不适和肝肾损伤。因此寻找疗效显著、安全可靠的调血脂药一直是医药工作者长期研究的课题。综述基于Pubmed上关于人高脂血症(胆固醇、三酰甘油、LDL-C、HDL-L)主要治疗药物的相关研究,对近年来调血脂药物研究进展进行综述。 Hyperlipidemia, the risk factor of atherosclerosis, closely related to the coronary heart disease, stroke, and the artery stenosis disease, is seriously threatening human health. Statins for the exact curative effects, has become the first choice to the most of the doctors in clinic. However, a large dosage of statins would cause muscle poison and associated increase in the hepatic transaminases, which is not suitable for all the cardiovascular diseases. In addition, Fibrates and niacin sequestrants would causee discomfort of gastrointestinal tract and damage of liver and kidney. Therefore, looking for the safe and reliable lipid-lowering drug with remarkable curative effect has been a project with long-term research for medicinal workers. This article reviewed the studies on new hypolipidemic drugs in recent years, which could mainly treat the hyperlipidemia (cholesterol, triglyceride, LDL-C, and HDL-L) based on the papers in the Pubmed.
出处 《现代药物与临床》 CAS 2012年第5期435-441,共7页 Drugs & Clinic
关键词 高脂血症 动脉粥样硬化 降脂药物 hyperlipidemia atherosclerosis hypolipidemic drug
  • 相关文献

参考文献39

  • 1Teslovich T M, Musunuru K, Smith A V, et al. Biological, clinical and population relevance of 95 locifor blood lipids [J]. Nature, 2010, 466(7307): 707-713.
  • 2Gillespie C D, Keenan N L, Miner J B, et al. Screening for lipid disorders among adults- National Health and Nutrition Examination Survey, United States, 2005-2008 [J]. Morbidity Mortality Weekly Rep, 2012, 61(2): 26-31.
  • 3Furiex Pharamceuticals Inc. Study of the safety and tolerability associated with PPD10558 versus atorvastatin in patients previously intolerant tostatins due to statin-associated myalgia (SAM) [EB/OL], (2011-09-23) [2011-12-19]. http://clinicaltrials.gov/ct2/results?term=ppd 10558.
  • 4Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review andmeta- analysis [J]. Lancet, 2010, 375(9729): 1875-1884.
  • 5HPS2-THRIVE investigators. A randomized trial of the long-term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant. [EB/OL]. (2007-04- 17) [2009-02-02]. http://clinicaltrials.gov/ct2/ show/ NCT00461630.
  • 6王应军,王磊,胡宾,王薇薇.降血脂药物的研究进展[J].中国民族民间医药,2011,20(9):30-31. 被引量:6
  • 7Wierzbicki A S, Hardman T, Prince W T. Future challenges for microsomal transport protein inhibitors [J].Curr Vase Pharmacol, 2009, 7(3): 277-286.
  • 8Samaha F F, McKenney J, Bloedon L T, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hyper cholesterolemia [J]. Nat Clin Pract Cardiovasc Med, 2008, 5(8): 497-505.
  • 9Meuwese M C, de de Groot E, Duivenvoorden R, et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. [J]. J Am Med Assoc, 2009, 301(11): 1131-1139.
  • 10Yoshinaka Y, Shibata H, Kobayashi H, et al. A selective ACAT-1. inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice [J]. Atherosclerosis, 2010, 213(1): 85-91.

二级参考文献9

  • 1Knopp R H. drug treatment of lipiddisorders [J]. New Eng J Med, 1999, 341 (7) : 498.
  • 2The medical letter, Inc. Choice of lipid- regulatingdrugs [ J ]. Meal Lettdrug Ther2001 , 43 (1105) : 43.
  • 3Insua A , Massari F , Rodriguez J, et al . Fenofibrate and gemfibrozil for treatment of types Iia and Iib primary hyperlipoproteinmia : a randomizeddouble blind crossover study[J]. Endocr Pract , 2002 , 8 (2) : 96.
  • 4Keating GM, Ormordd. Micronised fenofibrate : an updated review of its dinical efficacy in the management ofdyslipidaemia[J]. drugs , 2002 , 62 (13): 1909.
  • 5Capuzzid M, Guyton J R , Morgan J M, et al. Efficacy and safety of an extended -release niacin (Niaspan) : a long term study [J]. Am J Cardiol , 1998, 82 (12A) : 74.
  • 6Guyton J R , Goldberg A C , Kreisberg R A , et al . Effectiveness of once nightlydasing of extended - release niacin alone and in combination for hypereholesterolemia[J]. Am J Cardiol , 1998 , 82 (6) : 737.
  • 7Dujovne C A , Ettinger M P , McNeer J F , et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia [J].Am J Cardiol , 2002 , 90 (10) : 1092.
  • 8Insull WJ , Koren M, Davignon J , et al. Efficacy and short - term safety of a new ACAT inhibitor, avasimibe , on lipids , lipoproteins, and apolipoproteins , in patients with combied hyperlipidemia[J]. Atherosclerosis , 2001 , 157 (1) : 137.
  • 9王宇辉,周超凡.中药降脂研究进展[J].中国中药杂志,1999,24(3):184-186. 被引量:99

共引文献5

同被引文献333

引证文献34

二级引证文献153

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部